Use of bortezomib as anti-humoral therapy in kidney transplantation

Journal of Korean Medical Science

Volumn 29, Issue 5, 2014, Pages 648-651

  Yang, Keun Suk ^a   Jeon, Howook ^a   Park, Youngjae ^a   Jo, Ik Hyun ^a   Kim, Ji Il ^b   Moon, In Sung ^b   Choi, Bum Soon ^a   Park, Cheol Whee ^a   Yang, Chul Woo ^a   Kim, Yong Soo ^a   Chung, Byung Ha ^a  

^a Division of Nephrology   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Anti humoral therapy; Antibody mediated rejection; Bortezomib; Desensitization; Kidney transplantation

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; HLA ANTIGEN; PYRAZINE DERIVATIVE;

ADULT; DESENSITIZATION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOLOGY; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROCEDURES; SURGERY; TREATMENT OUTCOME;

ADULT; BORONIC ACIDS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME;

EID: 84910633883     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.5.648     Document Type: Article

References (12)

1. Yoon HE, Hyoung BJ, Hwang HS, Lee SY, Jeon YJ, Song JC, Oh EJ, Park SC, Choi BS, Moon IS, et al. Successful renal transplantation with desensitization in highly sensitized patients: a single center experience. J Korean Med Sci 2009; 24: S148-55.
2. Everly MJ, Rebellato LM, Ozawa M, Briley KP, Catrou PG, Haisch CE, Terasaki PI. Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection. Transplantation 2010; 89: 962-7.
3. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011; 6: 922-36.
4. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 2007; 7: 402-7.
5. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, Roy-Chaudhury P, Govil A, Mogilishetty G, Rike AH, et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 2008; 86: 1754-61.
6. Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201-9.
7. Chung BH, Lee JY, Kang SH, Sun IO, Choi SR, Park HS, Kim JI, Moon IS, Choi BS, Park CW, et al. Comparison of clinical outcome between high and low baseline anti-ABO antibody titers in ABO-incompatible kidney transplantation. Ren Fail 2011; 33: 150-8.
8. Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, Solez K, Cendales L, Demetris AJ, Drachenberg CB, et al. Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-70.
9. Nigos JG, Arora S, Nath P, Hussain SM, Marcus RJ, Ko TY, Sureshkumar KK. Treatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with a bortezomib-based regimen. Exp Clin Transplant 2012; 10: 609-13.
10. Flechner SM, Fatica R, Askar M, Stephany BR, Poggio E, Koo A, Banning S, Chiesa-Vottero A, Srinivas T. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90: 1486-92.
11. Wahrmann M, Haidinger M, Körmöczi GF, Weichhart T, Säemann MD, Geyeregger R, Kikić Z, Prikoszovich T, Drach J, Böhmig GA. Effect of the proteasome inhibitor bortezomib on humoral immunity in two presensitized renal transplant candidates. Transplantation 2010; 89: 1385-90.
12. Sadaka B, Alloway RR, Woodle ES. Clinical and investigational use of proteasome inhibitors for transplant rejection. Expert Opin Investig Drugs 2011; 20: 1535-42.